Vivos Inc. Strengthens Strategic Collaboration with Exubrion Therapeutics
Vivos Inc. (OTCQB: RDGL) announced on October 29, 2025 an expanded strategic collaboration with Exubrion Therapeutics to advance targeted radioactive isotope technology for multiple companion-animal indications.
Agreed areas include shared clinic relationships, licensing coordination, and manufacturing optimization, building on prior cooperation on device classification, clinician training modules, and educational seminars. Both CEOs said the partnership aims to align scientific and operational strengths to accelerate innovation across distinct veterinary therapy markets.
Vivos Inc. (OTCQB: RDGL) ha annunciato il 29 ottobre 2025 una espansione della collaborazione strategica con Exubrion Therapeutics per avanzare la tecnologia a isotopi radioattivi mirata per molte indicazioni di animali da compagnia.
Le aree concordate includono relazioni cliniche condivise, coordinazione delle licenze e ottimizzazione della produzione, basandosi sulla precedente cooperazione su classificazione dei dispositivi, moduli di formazione per i clinici e seminari educativi. Entrambi i CEO hanno affermato che la partnership punta ad allineare forze scientifiche e operative per accelerare l'innovazione nei vari mercati delle terapie veterinarie.
Vivos Inc. (OTCQB: RDGL) anunció el 29 de octubre de 2025 una colaboración estratégica ampliada con Exubrion Therapeutics para avanzar la tecnología de isótopos radiactivos focalizados para múltiples indicaciones en animales de compañía.
Las áreas acordadas incluyen relaciones clínicas compartidas, coordinación de licencias y optimización de la fabricación, basándose en la cooperación previa sobre clasificación de dispositivos, módulos de capacitación para clínicos y seminarios educativos. Ambos directores ejecutivos dijeron que la asociación busca alinear fortalezas científicas y operativas para acelerar la innovación en los distintos mercados de terapias veterinarias.
Vivos Inc. (OTCQB: RDGL)는 2025년 10월 29일에 Exubrion Therapeutics와의 확대된 전략적 협력을 발표하여 다수의 반려동물 대상 적정 방사성 동위원소 기술을 발전시킵니다.
합의 영역에는 공유 임상 관계, 라이선스 조정, 제조 최적화가 포함되며, 기기 분류, 임상의 교육 모듈, 교육 세미나에 대한 이전 협력을 바탕으로 합니다. 양사의 CEO는 이 파트너십이 과학적 및 운영상의 강점을 조화시켜 서로 다른 수의학 치료 시장에서 혁신을 가속화하는 것을 목표로 한다고 밝혔습니다.
Vivos Inc. (OTCQB: RDGL) a annoncé le 29 octobre 2025 une collaboration stratégique élargie avec Exubrion Therapeutics pour faire progresser la technologie des isotope radioactifs ciblés pour plusieurs indications chez les animaux de compagnie.
Les domaines convenus comprennent des relations cliniques partagées, la coordination des licences et l'optimisation de la fabrication, s'appuyant sur la coopération antérieure en matière de classification des dispositifs, de modules de formation des cliniciens et de séminaires éducatifs. Les deux PDG ont déclaré que le partenariat vise à aligner les forces scientifiques et opérationnelles pour accélérer l'innovation sur des marchés thérapeutiques vétérinaires distincts.
Vivos Inc. (OTCQB: RDGL) gab am 29. Oktober 2025 eine erweiterte strategische Zusammenarbeit mit Exubrion Therapeutics bekannt, um die Technologie radioaktiver Ziel-Isotope für mehrere Indikationen bei Haustieren voranzutreiben.
Vereinbarte Bereiche umfassen gemeinsame klinische Beziehungen, Lizenzkoordination und Produktionsoptimierung, aufbauend auf früherer Zusammenarbeit bei der Gerätekategorisierung, Schulungsmodule für Kliniker und Bildungsseminaren. Beide CEOs sagten, dass die Partnerschaft darauf abzielt, wissenschaftliche und operative Stärken auszurichten, um Innovationen in unterschiedlichen Märkten der tierärztlichen Therapien zu beschleunigen.
Vivos Inc. (OTCQB: RDGL) أعلنت في 29 أكتوبر 2025 عن توسيع التعاون الاستراتيجي مع Exubrion Therapeutics لتطوير تكنولوجيا النظائر المشعة المستهدفة لعِدّة مؤشرات لدى الحيوانات الأليفة المصاحبة.
تشمل المجالات المتفق عليها علاقات عيادية مشتركة، تنسيق التراخيص، وتحسين التصنيع، مبنية على التعاون السابق في تصنيف الأجهزة، ووحدات تدريب الأطباء، والندوات التعليمية. قال كلا المدراء التنفيذيين إن الشراكة تهدف إلى مواءمة القوى العلمية والتشغيلية لتسريع الابتكار عبر أسواق علاجات الطب البيطري المختلفة.
Vivos Inc. (OTCQB: RDGL) 于 2025年10月29日 宣布与 Exubrion Therapeutics 扩大战略合作，以推进针对多种伴侣动物适应症的定向放射性同位素技术。
商定的领域包括 共享临床关系、许可协调和制造优化，在先前关于设备分类、临床医生培训模块和教育研讨会的合作基础上。两位首席执行官表示，该伙伴关系旨在协调科学与运营优势，以加速在不同兽医治疗市场中的创新。
- None.
- None.
Kennewick, WA, Oct. 29, 2025 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL) today announced enhanced cooperation with Exubrion Therapeutics to advance the use of targeted radioactive isotope technology for multiple indications in companion animals.
The two companies have agreed to broaden their joint efforts in several key areas — including shared clinic relationships, licensing coordination, and manufacturing optimization. These initiatives build upon prior collaborations involving device classification, development of clinician training modules, and educational seminars.
“Our companies complement one another exceptionally well,” said Dr. Michael K. Korenko, Chief Executive Officer of Vivos Inc. “Exubrion’s focus on treating osteoarthritis pain in companion animals and Vivos’s work in cancer therapy represent distinct markets, enabling collaboration without competitive conflict. By aligning our scientific and operational strengths, we can accelerate innovation and efficiency across both organizations.”
Dr. Korenko added, “It is our shared responsibility to continuously pursue improvements that drive success. With only a limited number of companies developing therapeutic applications of radioactive isotopes, cooperative innovation is key to advancing this field.”
“I’m excited to collaborate with the Vivos team to help further this important work,” said Jennifer Kirk, Chief Executive Officer of Exubrion Therapeutics. “Together, we can accelerate progress in advancing the use of radioisotopes as a powerful and versatile technology platform with wide-ranging potential.”
About Vivos Inc.
Vivos Inc. (OTCQB: RDGL) is a radiotherapeutic company developing innovative isotope-based products for cancer treatment and other therapeutic applications. Its core technologies — RadioGel® for human use and IsoPet® for veterinary applications — are designed to precisely deliver therapeutic radiation to targeted tumor sites while minimizing exposure to surrounding healthy tissue. For more information, visit www.VivosInc.com.
About Exubrion Therapeutics
Exubrion Therapeutics is a veterinary radiotherapeutics company dedicated to improving the lives of companion animals through advanced radioisotope technology. The company’s lead product, Synovetin OA®, is an innovative, minimally invasive treatment for osteoarthritis that targets the source of the disease and provides long-lasting joint pain relief. Learn more at www.Exubrion.com.
Michael K. Korenko, Sc.D.
Chief Executive Officer, Vivos Inc.
Email: MKorenko@RadioGel.com
Follow Vivos Inc. on X (Twitter): @VivosIncUSA
Learn more about RadioGel® and IsoPet® at www.VivosInc.com
Safe Harbor Statement
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, identified by terms such as “will,” “expects,” “plans,” “anticipates,” and “intends.” These statements involve risks and uncertainties that could cause actual results to differ materially, including challenges in executing business strategies, economic conditions, competition, regulatory changes, delays in clinic certifications, and other factors beyond the control of Vivos Inc. For a detailed discussion of these risks, please refer to the company’s filings with the Securities and Exchange Commission.
FAQ
What did Vivos (RDGL) announce on October 29, 2025 regarding Exubrion Therapeutics?
How does the Vivos and Exubrion collaboration affect Vivos (RDGL) operations?
Which indications will Vivos (RDGL) and Exubrion focus on together?
Does the Vivos and Exubrion agreement include clinician training for RDGL-related technologies?
Who are the CEOs commenting on the Vivos (RDGL) and Exubrion partnership?
Will the Vivos (RDGL) collaboration change manufacturing for radioisotope therapies?
